董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lonnel Coats | 男 | Chief Executive Officer and Director | 58 | 386.07万美元 | 未持股 | 2023-03-03 |
| Samuel L. Barker | 男 | Director | 82 | 11.71万美元 | 未持股 | 2023-03-03 |
| Christopher J. Sobecki | 男 | Director | 66 | 8.96万美元 | 未持股 | 2023-03-03 |
| Judith L. Swain | 女 | Director | 76 | 10.46万美元 | 未持股 | 2023-03-03 |
| Philippe J. Amouyal | 男 | Director | 66 | 9.71万美元 | 未持股 | 2023-03-03 |
| Raymond Debbane | 男 | Chairman of the Board | 70 | 12.96万美元 | 未持股 | 2023-03-03 |
| Robert J. Lefkowitz | 男 | Director | 81 | 9.46万美元 | 未持股 | 2023-03-03 |
| Alan S. Nies | 男 | Director | 87 | 8.96万美元 | 未持股 | 2023-03-03 |
| Frank P. Palantoni | 男 | Director | 67 | 11.46万美元 | 未持股 | 2023-03-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lonnel Coats | 男 | Chief Executive Officer and Director | 58 | 386.07万美元 | 未持股 | 2023-03-03 |
| Brian T. Crum | 男 | Senior Vice President and General Counsel | 50 | 120.92万美元 | 未持股 | 2023-03-03 |
| Kristen L. Alexander | 女 | Vice President, Finance and Accounting | 55 | 未披露 | 未持股 | 2023-03-03 |
| Kenneth B. Kassler Taub | 男 | Senior Vice President, Regulatory and Quality Assurance | 66 | 未披露 | 未持股 | 2023-03-03 |
| Kiernan A. Seth | 男 | Vice President and Chief Commercial Officer | 56 | 未披露 | 未持股 | 2023-03-03 |
| Craig B. Granowitz | 男 | Senior Vice President and Chief Medical Officer | 58 | 未披露 | 未持股 | 2023-03-03 |
| Wendy E. McDermott | 女 | Vice President, Human Resources | 52 | 未披露 | 未持股 | 2023-03-03 |
| Jeffrey L. Wade | 男 | President and Chief Financial Officer | 58 | 162.95万美元 | 未持股 | 2023-03-03 |
| Alan J. Main | 男 | Executive Vice President, Innovation and Chemical Sciences | 69 | 130.53万美元 | 未持股 | 2023-03-03 |
董事简历
中英对照 | 中文 | 英文- Lonnel Coats
-
Lonnel Coats，2014年7月以来，一直担任本公司的总裁、首席执行官、董事。1996年至2014年6月，他在Eisai Inc. 、Eisai Corporation of North America担任过一系列领导职务；最后的是首席执行官，2010年至2014年6月；2004-2010，担任其总裁、首席运营官。加入Eisai之前，他在Janssen Pharmaceuticals, Inc工作了8年，担任过各种管理、销售职务，这是Johnson & Johnson的分部。他在Oakland University获得公共管理学士学位。
Lonnel Coats,has been Lexicon Pharmaceuticals, Inc. chief executive officer and a director since July 2014. Mr. Coats previously served in a series of executive leadership positions at Eisai Inc. and Eisai Corporation of North America, where he worked for 18 years before joining Lexicon Pharmaceuticals, Inc. company, most recently as chief executive officer from 2010 to 2014. Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he held a variety of management and sales positions. Mr. Coats serves as a director of Blueprint Medicines Corporation and Verve Therapeutics, Inc., and holds a B.S. from Oakland University. - Lonnel Coats，2014年7月以来，一直担任本公司的总裁、首席执行官、董事。1996年至2014年6月，他在Eisai Inc. 、Eisai Corporation of North America担任过一系列领导职务；最后的是首席执行官，2010年至2014年6月；2004-2010，担任其总裁、首席运营官。加入Eisai之前，他在Janssen Pharmaceuticals, Inc工作了8年，担任过各种管理、销售职务，这是Johnson & Johnson的分部。他在Oakland University获得公共管理学士学位。
- Lonnel Coats,has been Lexicon Pharmaceuticals, Inc. chief executive officer and a director since July 2014. Mr. Coats previously served in a series of executive leadership positions at Eisai Inc. and Eisai Corporation of North America, where he worked for 18 years before joining Lexicon Pharmaceuticals, Inc. company, most recently as chief executive officer from 2010 to 2014. Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he held a variety of management and sales positions. Mr. Coats serves as a director of Blueprint Medicines Corporation and Verve Therapeutics, Inc., and holds a B.S. from Oakland University.
- Samuel L. Barker
-
Samuel L. Barker，博士；自2000年3月以来担任董事，从2005年到2012年担任董事会主席。2001年，他共同创立 Clearview Projects公司——为生物制药公司提供合作和交易服务的提供者，并从2003年到2004年担任总裁兼首席执行官。他在百时美施贵宝公司（Bristol-Myers Squibb Company）担任过一系列的领导职务，直到1999年退休。他在百时美施贵宝的职务包括在1998年任全球特许经营管理和战略在执行副总裁，从1992年到1997年任美国药品总裁，从1990年到1992年任百时美施贵宝洲际商业运作总裁。1990年之前，他在美施贵宝制药担任研发、制造、财务、业务开发及销售和营销的高管职位。他目前从2006年到2009年担任 Cadence Pharmaceuticals有限公司和AtheroGenics有限公司的董事。他持有亨德森州立大学（Henderson State College）学士学位，阿肯色大学（University of Arkansas）硕士学位，以及普渡大学（Purdue University）的博士学位。
Samuel L. Barker has been a director since March 2000 and served as chairman of our board of directors from 2005 to 2012. Dr. Barker previously co-founded and served as president and chief executive officer of Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies. Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as executive vice president, Worldwide Franchise Management and Strategy; president, United States Pharmaceuticals; and president, Bristol-Myers Squibb Intercontinental Commercial Operations. Dr. Barker also previously held executive positions in research and development, manufacturing, finance, business development and sales and marketing at Squibb Pharmaceuticals. Dr. Barker currently serves as a director of Cyclacel Pharmaceuticals, Inc. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University. - Samuel L. Barker，博士；自2000年3月以来担任董事，从2005年到2012年担任董事会主席。2001年，他共同创立 Clearview Projects公司——为生物制药公司提供合作和交易服务的提供者，并从2003年到2004年担任总裁兼首席执行官。他在百时美施贵宝公司（Bristol-Myers Squibb Company）担任过一系列的领导职务，直到1999年退休。他在百时美施贵宝的职务包括在1998年任全球特许经营管理和战略在执行副总裁，从1992年到1997年任美国药品总裁，从1990年到1992年任百时美施贵宝洲际商业运作总裁。1990年之前，他在美施贵宝制药担任研发、制造、财务、业务开发及销售和营销的高管职位。他目前从2006年到2009年担任 Cadence Pharmaceuticals有限公司和AtheroGenics有限公司的董事。他持有亨德森州立大学（Henderson State College）学士学位，阿肯色大学（University of Arkansas）硕士学位，以及普渡大学（Purdue University）的博士学位。
- Samuel L. Barker has been a director since March 2000 and served as chairman of our board of directors from 2005 to 2012. Dr. Barker previously co-founded and served as president and chief executive officer of Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies. Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as executive vice president, Worldwide Franchise Management and Strategy; president, United States Pharmaceuticals; and president, Bristol-Myers Squibb Intercontinental Commercial Operations. Dr. Barker also previously held executive positions in research and development, manufacturing, finance, business development and sales and marketing at Squibb Pharmaceuticals. Dr. Barker currently serves as a director of Cyclacel Pharmaceuticals, Inc. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University.
- Christopher J. Sobecki
-
Christopher J. Sobecki，自2007年8月起担任董事，并于1989年加入Invus Group，LLC，担任董事总经理。Sobecki先生目前是WW，Inc.，以及Invus投资的多家私营公司的董事。他拥有普渡大学工业工程学士学位和哈佛大学工商管理硕士学位。
Christopher J. Sobecki has been a director since August 2007 and is a managing director of The Invus Group, LLC, which he joined in 1989. Mr. Sobecki is currently a director of WW, Inc., as well as a number of private companies in which Invus has invested. He holds a B.S. in industrial engineering from Purdue University and an M.B.A. from Harvard University. - Christopher J. Sobecki，自2007年8月起担任董事，并于1989年加入Invus Group，LLC，担任董事总经理。Sobecki先生目前是WW，Inc.，以及Invus投资的多家私营公司的董事。他拥有普渡大学工业工程学士学位和哈佛大学工商管理硕士学位。
- Christopher J. Sobecki has been a director since August 2007 and is a managing director of The Invus Group, LLC, which he joined in 1989. Mr. Sobecki is currently a director of WW, Inc., as well as a number of private companies in which Invus has invested. He holds a B.S. in industrial engineering from Purdue University and an M.B.A. from Harvard University.
- Judith L. Swain
-
Judith L. Swain，自2007年9月起任董事。她是是新加坡临床科学研究所顶级执行董事及新加坡国立大学的医学 Lien Chow教授。她也是新加坡全国医疗集团（National Healthcare Group）的董事，2005年至2006年，她是圣地亚哥加州大学（ University of California）转化医学的院长。她从1997年至2005年担任斯坦福大学医学部主席，先前是宾夕法尼亚大学（University of Pennsylvania）和杜克大学（Duke University）的医学院教师。她目前是Avacen有限公司的董事。先前，她担任过一系列国内和国际领导职务，且在一些生物医学技术公司担任科学咨询委员会董事或成员，且共同创立了Synecor有限公司。她持有洛杉矶加州大学（University of California）学士学位和圣地亚哥加州大学医学博士学位。
Judith L. Swain has been a director since September 2007. Dr. Swain is a visiting professor of medicine at the National University of Singapore and chief medical officer of Physiowave, Inc. She previously served as founding director of the Singapore Institute for Clinical Sciences, dean for translational medicine at the University of California, San Diego, chair of the Department of Medicine at Stanford University, and on the medical faculties of the University of Pennsylvania and Duke University. She has previously served in a number of national and international leadership roles and as a director or member of the scientific advisory boards for a number of biomedical technology companies and is co-founder of Synecor, LLC. Dr. Swain received her B.S. from the University of California, Los Angeles and her M.D. from the University of California, San Diego. - Judith L. Swain，自2007年9月起任董事。她是是新加坡临床科学研究所顶级执行董事及新加坡国立大学的医学 Lien Chow教授。她也是新加坡全国医疗集团（National Healthcare Group）的董事，2005年至2006年，她是圣地亚哥加州大学（ University of California）转化医学的院长。她从1997年至2005年担任斯坦福大学医学部主席，先前是宾夕法尼亚大学（University of Pennsylvania）和杜克大学（Duke University）的医学院教师。她目前是Avacen有限公司的董事。先前，她担任过一系列国内和国际领导职务，且在一些生物医学技术公司担任科学咨询委员会董事或成员，且共同创立了Synecor有限公司。她持有洛杉矶加州大学（University of California）学士学位和圣地亚哥加州大学医学博士学位。
- Judith L. Swain has been a director since September 2007. Dr. Swain is a visiting professor of medicine at the National University of Singapore and chief medical officer of Physiowave, Inc. She previously served as founding director of the Singapore Institute for Clinical Sciences, dean for translational medicine at the University of California, San Diego, chair of the Department of Medicine at Stanford University, and on the medical faculties of the University of Pennsylvania and Duke University. She has previously served in a number of national and international leadership roles and as a director or member of the scientific advisory boards for a number of biomedical technology companies and is co-founder of Synecor, LLC. Dr. Swain received her B.S. from the University of California, Los Angeles and her M.D. from the University of California, San Diego.
- Philippe J. Amouyal
-
Philippe J. Amouyal，自2002年11月起任董事。他自1999年起任The Invus Group有限责任公司的董事总经理。先前，他曾是马萨诸塞州波士顿的波士顿咨询集团（Boston Consulting Group）的副总裁兼董事。他持有Ecole Centrale de Paris的工程硕士学位和管理学学位，且是麻省理工学院（the Massachusetts Institute of Technology）政策替换中心（ the Center for Policy Alternatives）的研究员。他是Lexicon Pharmaceuticals有限公司薪酬委员会董事兼成员，且是一些私人公司的董事及成员；Artal或Invus, L.P.是这些私人公司的股东。
Philippe J. Amouyal has been a director since August 2007 and is a managing director of The Invus Group, LLC, a position he has held since 1999. Previously, Mr. Amouyal was a vice president and director of The Boston Consulting Group, Inc. in Boston, Massachusetts, where he coordinated the global technology and electronics practice through most of the 1990s. Mr. Amouyal also serves as director at a number of private companies in which Invus has invested. He previously served as a director of WW, Inc. from 2002 until February 2019 and of Blue Buffalo Pet Products, Inc. from 2007 until April 2018 when Blue Buffalo was acquired by General Mills, Inc. Mr. Amouyal holds an M.S. in engineering and a DEA in management from Ecole Centrale de Paris and was a research fellow at the Center for Policy Alternatives of the Massachusetts Institute of Technology. - Philippe J. Amouyal，自2002年11月起任董事。他自1999年起任The Invus Group有限责任公司的董事总经理。先前，他曾是马萨诸塞州波士顿的波士顿咨询集团（Boston Consulting Group）的副总裁兼董事。他持有Ecole Centrale de Paris的工程硕士学位和管理学学位，且是麻省理工学院（the Massachusetts Institute of Technology）政策替换中心（ the Center for Policy Alternatives）的研究员。他是Lexicon Pharmaceuticals有限公司薪酬委员会董事兼成员，且是一些私人公司的董事及成员；Artal或Invus, L.P.是这些私人公司的股东。
- Philippe J. Amouyal has been a director since August 2007 and is a managing director of The Invus Group, LLC, a position he has held since 1999. Previously, Mr. Amouyal was a vice president and director of The Boston Consulting Group, Inc. in Boston, Massachusetts, where he coordinated the global technology and electronics practice through most of the 1990s. Mr. Amouyal also serves as director at a number of private companies in which Invus has invested. He previously served as a director of WW, Inc. from 2002 until February 2019 and of Blue Buffalo Pet Products, Inc. from 2007 until April 2018 when Blue Buffalo was acquired by General Mills, Inc. Mr. Amouyal holds an M.S. in engineering and a DEA in management from Ecole Centrale de Paris and was a research fellow at the Center for Policy Alternatives of the Massachusetts Institute of Technology.
- Raymond Debbane
-
Raymond Debbane，自2007年8月起担任董事，并于2012年2月成为董事会主席。Debbane先生是Invus Group，LLC的总裁兼首席执行官，该公司于1985年在纽约成立，是总部位于比荷卢的Artal Group S.A.的独家投资顾问。2007年至2018年4月，他曾担任Blue Buffalo Pet Products，Inc.的董事，当时Blue Buff alo被General Mills，Inc.收购。在成立Invus Group之前，Debbane先生是The Boston Consulting Group，Inc.巴黎办事处的经理，曾为多家主要的欧洲和国际公司提供咨询服务。Debbane先生拥有斯坦福大学的工商管理硕士学位，加州大学戴维斯分校的食品科学与技术硕士学位，以及贝鲁特美国大学的农业科学与农业工程学士学位。
Raymond Debbane has been a director since August 2007 and became chairman of Lexicon Pharmaceuticals, Inc.'s board of directors in February 2012. Mr. Debbane is president and chief executive officer of The Invus Group, LLC, which he founded in New York in 1985 as the exclusive investment advisor of Benelux-based Artal Group S.A. Mr. Debbane serves as chairman of the board of directors of WW, Inc. and as chairman or director of a number of private companies in which Invus and Artal Group S.A. have invested. He previously served as a director of Blue Buffalo Pet Products, Inc. from 2007 until April 2018 when Blue Buffalo was acquired by General Mills, Inc. Before founding The Invus Group, Mr. Debbane was a manager in the Paris office of The Boston Consulting Group, Inc., where he did consulting work for a number of major European and international companies. Mr. Debbane holds an M.B.A. from Stanford University, an M.S. in food science and technology from the University of California at Davis, and a B.S in agricultural sciences and agricultural engineering from American University of Beirut. - Raymond Debbane，自2007年8月起担任董事，并于2012年2月成为董事会主席。Debbane先生是Invus Group，LLC的总裁兼首席执行官，该公司于1985年在纽约成立，是总部位于比荷卢的Artal Group S.A.的独家投资顾问。2007年至2018年4月，他曾担任Blue Buffalo Pet Products，Inc.的董事，当时Blue Buff alo被General Mills，Inc.收购。在成立Invus Group之前，Debbane先生是The Boston Consulting Group，Inc.巴黎办事处的经理，曾为多家主要的欧洲和国际公司提供咨询服务。Debbane先生拥有斯坦福大学的工商管理硕士学位，加州大学戴维斯分校的食品科学与技术硕士学位，以及贝鲁特美国大学的农业科学与农业工程学士学位。
- Raymond Debbane has been a director since August 2007 and became chairman of Lexicon Pharmaceuticals, Inc.'s board of directors in February 2012. Mr. Debbane is president and chief executive officer of The Invus Group, LLC, which he founded in New York in 1985 as the exclusive investment advisor of Benelux-based Artal Group S.A. Mr. Debbane serves as chairman of the board of directors of WW, Inc. and as chairman or director of a number of private companies in which Invus and Artal Group S.A. have invested. He previously served as a director of Blue Buffalo Pet Products, Inc. from 2007 until April 2018 when Blue Buffalo was acquired by General Mills, Inc. Before founding The Invus Group, Mr. Debbane was a manager in the Paris office of The Boston Consulting Group, Inc., where he did consulting work for a number of major European and international companies. Mr. Debbane holds an M.B.A. from Stanford University, an M.S. in food science and technology from the University of California at Davis, and a B.S in agricultural sciences and agricultural engineering from American University of Beirut.
- Robert J. Lefkowitz
-
Robert J. Lefkowitz，2001年2月起担任董事。Lefkowitz博士是James B. Duke医学教授，生物化学教授，杜克大学医学中心霍华德休斯医学研究所研究员，自1973年以来一直在该中心任职。Lefkowitz博士是美国国家科学院的成员，并因其研究获得了50多个主要奖项，包括2012年诺贝尔化学奖、邵氏奖、奥尔巴尼医学中心奖和2007年国家科学奖。他在哥伦比亚大学获得学士学位，在哥伦比亚大学内科和外科医生学院获得医学博士学位。
Robert J. Lefkowitz has been a director since February 2001. Dr. Lefkowitz is the James B. Duke Professor of Medicine, professor of biochemistry and a Howard Hughes Medical Institute investigator at Duke University Medical Center, where he has served on the faculty since 1973. Dr. Lefkowitz is a member of the National Academy of Sciences and has received more than 50 major awards for his research, including the 2012 Nobel Prize in Chemistry, the Shaw Prize, the Albany Medical Center Prize and the 2007 National Medal of Science. Dr. Lefkowitz received his B.A. from Columbia University and his M.D. from Columbia University College of Physicians and Surgeons. - Robert J. Lefkowitz，2001年2月起担任董事。Lefkowitz博士是James B. Duke医学教授，生物化学教授，杜克大学医学中心霍华德休斯医学研究所研究员，自1973年以来一直在该中心任职。Lefkowitz博士是美国国家科学院的成员，并因其研究获得了50多个主要奖项，包括2012年诺贝尔化学奖、邵氏奖、奥尔巴尼医学中心奖和2007年国家科学奖。他在哥伦比亚大学获得学士学位，在哥伦比亚大学内科和外科医生学院获得医学博士学位。
- Robert J. Lefkowitz has been a director since February 2001. Dr. Lefkowitz is the James B. Duke Professor of Medicine, professor of biochemistry and a Howard Hughes Medical Institute investigator at Duke University Medical Center, where he has served on the faculty since 1973. Dr. Lefkowitz is a member of the National Academy of Sciences and has received more than 50 major awards for his research, including the 2012 Nobel Prize in Chemistry, the Shaw Prize, the Albany Medical Center Prize and the 2007 National Medal of Science. Dr. Lefkowitz received his B.A. from Columbia University and his M.D. from Columbia University College of Physicians and Surgeons.
- Alan S. Nies
-
Alan S. Nies，自2003年11月起担任董事，自2003年3月起担任医学咨询委员会董事长。1992年至2002年，他在Merck & Co. 有限公司担任了许多高级管理职务，包括临床科学高级副总裁。在加入Merck & Co. 之前，他在科罗拉多大学健康科学中心担任医学与药理学教授以及临床药理学部负责人达15年之久。他持有斯坦福大学（Stanford University）学士学位和哈佛医学院（ Harvard Medical School）医学博士学位。
Alan S. Nies has been a director since November 2003. Dr. Nies served in a series of senior management positions during ten years at Merck & Co. Inc. until his retirement in 2002 including senior vice president, clinical sciences. Prior to joining Merck, Dr. Nies spent fifteen years as professor of medicine and pharmacology and head of the Division of Clinical Pharmacology at the University of Colorado Health Sciences Center. Dr. Nies holds a B.S. from Stanford University and an M.D. from Harvard Medical School. - Alan S. Nies，自2003年11月起担任董事，自2003年3月起担任医学咨询委员会董事长。1992年至2002年，他在Merck & Co. 有限公司担任了许多高级管理职务，包括临床科学高级副总裁。在加入Merck & Co. 之前，他在科罗拉多大学健康科学中心担任医学与药理学教授以及临床药理学部负责人达15年之久。他持有斯坦福大学（Stanford University）学士学位和哈佛医学院（ Harvard Medical School）医学博士学位。
- Alan S. Nies has been a director since November 2003. Dr. Nies served in a series of senior management positions during ten years at Merck & Co. Inc. until his retirement in 2002 including senior vice president, clinical sciences. Prior to joining Merck, Dr. Nies spent fifteen years as professor of medicine and pharmacology and head of the Division of Clinical Pharmacology at the University of Colorado Health Sciences Center. Dr. Nies holds a B.S. from Stanford University and an M.D. from Harvard Medical School.
- Frank P. Palantoni
-
Frank P. Palantoni，自2004年11月起任董事。他是一家为消费者和医疗保健行业提供服务的咨询公司Palantoni & Partners 有限责任公司的总裁。他从2011年至2013年任Central Garden & Pet Company的宠物和动物健康部总裁，2006年至2011年任一家处于早期阶段的消费性产品股本基金 P3 Capital Management有限责任公司的合伙人。1998年至2004年，他在Novartis AG担任了一系列高级管理职务，包括Gerber Products Company的全球总裁兼首席执行官，消费者健康部的运营首席执行官。在加入Novartis 之前，他在达能集团（The Danone Group）担任了许多高级管理职务。他持有塔夫斯大学（ Tufts University）学士学位和哥伦比亚大学（Columbia University）工商管理硕士学位。
Frank P. Palantoni has been a director since November 2004. Mr. Palantoni is chief executive officer of Laboratory M2 a clean technology company involved in animal health, crop protection and retail sectors. Mr. Palantoni was president of Palantoni & Partners LLC, an advisory firm for the consumer and health care industries, from 2013 to 2016. He previously served as president of the pet and animal health division of Central Garden & Pet Company, was a partner at P3 Capital Management LLC, an early stage consumer products equity fund, served as chief operating officer and chief executive officer of Prestige Brands Holding, Inc. and held a variety of senior management positions with Novartis AG, including president and chief executive officer, worldwide of the Gerber Products Company, and chief executive officer for North American operations of the Consumer Health Division. Prior to joining Novartis, he held a series of senior management positions with The Danone Group. Mr. Palantoni served as a director of Mondias Natural Products Inc. from 2017 until June 2020 and holds a B.S. from Tufts University and an M.B.A. from Columbia University. - Frank P. Palantoni，自2004年11月起任董事。他是一家为消费者和医疗保健行业提供服务的咨询公司Palantoni & Partners 有限责任公司的总裁。他从2011年至2013年任Central Garden & Pet Company的宠物和动物健康部总裁，2006年至2011年任一家处于早期阶段的消费性产品股本基金 P3 Capital Management有限责任公司的合伙人。1998年至2004年，他在Novartis AG担任了一系列高级管理职务，包括Gerber Products Company的全球总裁兼首席执行官，消费者健康部的运营首席执行官。在加入Novartis 之前，他在达能集团（The Danone Group）担任了许多高级管理职务。他持有塔夫斯大学（ Tufts University）学士学位和哥伦比亚大学（Columbia University）工商管理硕士学位。
- Frank P. Palantoni has been a director since November 2004. Mr. Palantoni is chief executive officer of Laboratory M2 a clean technology company involved in animal health, crop protection and retail sectors. Mr. Palantoni was president of Palantoni & Partners LLC, an advisory firm for the consumer and health care industries, from 2013 to 2016. He previously served as president of the pet and animal health division of Central Garden & Pet Company, was a partner at P3 Capital Management LLC, an early stage consumer products equity fund, served as chief operating officer and chief executive officer of Prestige Brands Holding, Inc. and held a variety of senior management positions with Novartis AG, including president and chief executive officer, worldwide of the Gerber Products Company, and chief executive officer for North American operations of the Consumer Health Division. Prior to joining Novartis, he held a series of senior management positions with The Danone Group. Mr. Palantoni served as a director of Mondias Natural Products Inc. from 2017 until June 2020 and holds a B.S. from Tufts University and an M.B.A. from Columbia University.
高管简历
中英对照 | 中文 | 英文- Lonnel Coats
Lonnel Coats，2014年7月以来，一直担任本公司的总裁、首席执行官、董事。1996年至2014年6月，他在Eisai Inc. 、Eisai Corporation of North America担任过一系列领导职务；最后的是首席执行官，2010年至2014年6月；2004-2010，担任其总裁、首席运营官。加入Eisai之前，他在Janssen Pharmaceuticals, Inc工作了8年，担任过各种管理、销售职务，这是Johnson & Johnson的分部。他在Oakland University获得公共管理学士学位。
Lonnel Coats,has been Lexicon Pharmaceuticals, Inc. chief executive officer and a director since July 2014. Mr. Coats previously served in a series of executive leadership positions at Eisai Inc. and Eisai Corporation of North America, where he worked for 18 years before joining Lexicon Pharmaceuticals, Inc. company, most recently as chief executive officer from 2010 to 2014. Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he held a variety of management and sales positions. Mr. Coats serves as a director of Blueprint Medicines Corporation and Verve Therapeutics, Inc., and holds a B.S. from Oakland University.- Lonnel Coats，2014年7月以来，一直担任本公司的总裁、首席执行官、董事。1996年至2014年6月，他在Eisai Inc. 、Eisai Corporation of North America担任过一系列领导职务；最后的是首席执行官，2010年至2014年6月；2004-2010，担任其总裁、首席运营官。加入Eisai之前，他在Janssen Pharmaceuticals, Inc工作了8年，担任过各种管理、销售职务，这是Johnson & Johnson的分部。他在Oakland University获得公共管理学士学位。
- Lonnel Coats,has been Lexicon Pharmaceuticals, Inc. chief executive officer and a director since July 2014. Mr. Coats previously served in a series of executive leadership positions at Eisai Inc. and Eisai Corporation of North America, where he worked for 18 years before joining Lexicon Pharmaceuticals, Inc. company, most recently as chief executive officer from 2010 to 2014. Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he held a variety of management and sales positions. Mr. Coats serves as a director of Blueprint Medicines Corporation and Verve Therapeutics, Inc., and holds a B.S. from Oakland University.
- Brian T. Crum
BrianT.Crum自2010年5月以来一直是我们的Vice President and General Counsel，自2001年加入我们公司以来曾担任一系列法律领导职务。他此前曾担任Brobeck，Phleger&Harrison LLP、Andrews&Kurth L.L.P.的律师事务所的公司证券律师，在那里他曾代表能源和信息技术行业的公司。Crum先生在德克萨斯大学（University of Texas）获得工商管理学士学位和法学博士学位。
Brian T. Crum,has been Lexicon Pharmaceuticals, Inc. senior vice president and general counsel since October 2021 and previously served in a series of legal leadership positions since joining Lexicon Pharmaceuticals, Inc. in 2001. Mr. Crum was previously a corporate securities attorney with the law firms of Brobeck, Phleger & Harrison LLP and Andrews & Kurth L.L.P., where he represented companies in the energy and information technology industries. Mr. Crum received his B.B.A. and J.D. from the University of Texas.- BrianT.Crum自2010年5月以来一直是我们的Vice President and General Counsel，自2001年加入我们公司以来曾担任一系列法律领导职务。他此前曾担任Brobeck，Phleger&Harrison LLP、Andrews&Kurth L.L.P.的律师事务所的公司证券律师，在那里他曾代表能源和信息技术行业的公司。Crum先生在德克萨斯大学（University of Texas）获得工商管理学士学位和法学博士学位。
- Brian T. Crum,has been Lexicon Pharmaceuticals, Inc. senior vice president and general counsel since October 2021 and previously served in a series of legal leadership positions since joining Lexicon Pharmaceuticals, Inc. in 2001. Mr. Crum was previously a corporate securities attorney with the law firms of Brobeck, Phleger & Harrison LLP and Andrews & Kurth L.L.P., where he represented companies in the energy and information technology industries. Mr. Crum received his B.B.A. and J.D. from the University of Texas.
- Kristen L. Alexander
Kristen L. Alexander自2021年9月起担任Lexicon Pharmaceuticals，Inc.财务和会计副总裁兼首席会计官，自2017年加入Lexicon Pharmaceuticals，Inc.以来一直担任财务总监。Alexander女士曾担任Johnson Specialty Tools，LLC的财务总监，并在Trican Well Services，L.P.、纳伯斯工业有限公司和Ernst & Young，LLP担任过各种财务和会计管理职位。亚历山大女士是一名注册会计师，在俄克拉荷马大学获得了学士学位。
Kristen L. Alexander,has been Lexicon Pharmaceuticals, Inc. vice president of finance and accounting and principal accounting officer since September 2021 and previously served as controller since joining Lexicon Pharmaceuticals, Inc. in 2017. Ms. Alexander previously served as controller of Johnson Specialty Tools, LLC and in a variety of finance and accounting management positions for Trican Well Services, L.P., Nabors Industries Ltd. and Ernst & Young, LLP. Ms. Alexander is a certified public accountant and received her B.B.A. from the University of Oklahoma.- Kristen L. Alexander自2021年9月起担任Lexicon Pharmaceuticals，Inc.财务和会计副总裁兼首席会计官，自2017年加入Lexicon Pharmaceuticals，Inc.以来一直担任财务总监。Alexander女士曾担任Johnson Specialty Tools，LLC的财务总监，并在Trican Well Services，L.P.、纳伯斯工业有限公司和Ernst & Young，LLP担任过各种财务和会计管理职位。亚历山大女士是一名注册会计师，在俄克拉荷马大学获得了学士学位。
- Kristen L. Alexander,has been Lexicon Pharmaceuticals, Inc. vice president of finance and accounting and principal accounting officer since September 2021 and previously served as controller since joining Lexicon Pharmaceuticals, Inc. in 2017. Ms. Alexander previously served as controller of Johnson Specialty Tools, LLC and in a variety of finance and accounting management positions for Trican Well Services, L.P., Nabors Industries Ltd. and Ernst & Young, LLP. Ms. Alexander is a certified public accountant and received her B.B.A. from the University of Oklahoma.
- Kenneth B. Kassler Taub
Kenneth B. Kassler Taub，医学博士自2021年10月起担任Lexicon Pharmaceuticals，Inc.负责监管事务和质量保证的高级副总裁，自2014年加入Lexicon Pharmaceuticals，Inc.以来曾担任临床运营副总裁和其他高级职务。Kassler-Taub博士曾在Becton Dickinson公司担任多个高级临床和医学领导职位，他在那里工作了12年，最近担任公司临床开发副总裁。在加入Becton Dickinson之前，Kassler-Taub博士在百时美施贵宝公司制药研究所工作了14年，在那里他担任过各种临床和药物安全职位。Kassler-Taub博士在阿默斯特学院获得学士学位，在波士顿大学医学院获得医学博士学位。
Kenneth B. Kassler Taub,M.D. has been Lexicon Pharmaceuticals, Inc. senior vice president, regulatory affairs and quality assurance since October 2021 and previously served as vice president, clinical operations and in other senior capacities since joining Lexicon Pharmaceuticals, Inc. in 2014. Dr. Kassler-Taub previously served in various senior clinical and medical leadership positions at Becton Dickinson and Company, where he worked for 12 years, most recently as vice president, corporate clinical development. Prior to joining Becton Dickinson, Dr. Kassler-Taub spent 14 years with Bristol-Myers Squibb Company Pharmaceutical Research Institute, where he held a variety of clinical and drug safety positions. Dr. Kassler-Taub received his B.A. from Amherst College and M.D. from the Boston University School of Medicine.- Kenneth B. Kassler Taub，医学博士自2021年10月起担任Lexicon Pharmaceuticals，Inc.负责监管事务和质量保证的高级副总裁，自2014年加入Lexicon Pharmaceuticals，Inc.以来曾担任临床运营副总裁和其他高级职务。Kassler-Taub博士曾在Becton Dickinson公司担任多个高级临床和医学领导职位，他在那里工作了12年，最近担任公司临床开发副总裁。在加入Becton Dickinson之前，Kassler-Taub博士在百时美施贵宝公司制药研究所工作了14年，在那里他担任过各种临床和药物安全职位。Kassler-Taub博士在阿默斯特学院获得学士学位，在波士顿大学医学院获得医学博士学位。
- Kenneth B. Kassler Taub,M.D. has been Lexicon Pharmaceuticals, Inc. senior vice president, regulatory affairs and quality assurance since October 2021 and previously served as vice president, clinical operations and in other senior capacities since joining Lexicon Pharmaceuticals, Inc. in 2014. Dr. Kassler-Taub previously served in various senior clinical and medical leadership positions at Becton Dickinson and Company, where he worked for 12 years, most recently as vice president, corporate clinical development. Prior to joining Becton Dickinson, Dr. Kassler-Taub spent 14 years with Bristol-Myers Squibb Company Pharmaceutical Research Institute, where he held a variety of clinical and drug safety positions. Dr. Kassler-Taub received his B.A. from Amherst College and M.D. from the Boston University School of Medicine.
- Kiernan A. Seth
Kiernan A. Seth博士自2021年10月起担任Lexicon Pharmaceuticals，Inc.副总裁兼首席商务官，自2014年加入Lexicon Pharmaceuticals，Inc.以来，曾担任一系列商业和医疗领导职位。赛斯博士曾在卫材公司担任肿瘤业务部门的执行董事和主管，并在百时美施贵宝公司、辉瑞公司和先灵葆雅公司担任过一系列营销职务。赛斯博士在诺福克州立大学获得了学士学位，在圣约瑟夫大学获得了工商管理硕士学位，在迈哈里医学院获得了博士学位。
Kiernan A. Seth, Ph.D,Ph.D. has been Lexicon Pharmaceuticals, Inc. vice president and chief commercial officer since October 2021 and previously served in a series of commercial and medical leadership positions since joining Lexicon Pharmaceuticals, Inc. in 2014. Dr. Seth previously served as executive director and head of the oncology business unit with Eisai, Inc. and in a series of marketing roles with Bristol-Myers Squibb Company, Pfizer Inc. and Schering Plough Corporation. Dr. Seth received his B.S. from Norfolk State University, his M.B.A. from St. Joseph's University and his Ph.D. from Meharry Medical College.- Kiernan A. Seth博士自2021年10月起担任Lexicon Pharmaceuticals，Inc.副总裁兼首席商务官，自2014年加入Lexicon Pharmaceuticals，Inc.以来，曾担任一系列商业和医疗领导职位。赛斯博士曾在卫材公司担任肿瘤业务部门的执行董事和主管，并在百时美施贵宝公司、辉瑞公司和先灵葆雅公司担任过一系列营销职务。赛斯博士在诺福克州立大学获得了学士学位，在圣约瑟夫大学获得了工商管理硕士学位，在迈哈里医学院获得了博士学位。
- Kiernan A. Seth, Ph.D,Ph.D. has been Lexicon Pharmaceuticals, Inc. vice president and chief commercial officer since October 2021 and previously served in a series of commercial and medical leadership positions since joining Lexicon Pharmaceuticals, Inc. in 2014. Dr. Seth previously served as executive director and head of the oncology business unit with Eisai, Inc. and in a series of marketing roles with Bristol-Myers Squibb Company, Pfizer Inc. and Schering Plough Corporation. Dr. Seth received his B.S. from Norfolk State University, his M.B.A. from St. Joseph's University and his Ph.D. from Meharry Medical College.
- Craig B. Granowitz
Craig B. Granowitz博士自2021年8月起担任Lexicon Pharmaceuticals，Inc.高级副总裁兼首席医疗官。格拉诺维茨博士自2016年起担任Amarin Corporation plc的首席医疗官。在加入Amarin之前，Granowitz博士曾担任默克公司高级副总裁兼全球医疗事务、全球人类健康主管，并在Schering-Plough Corporation担任过多个医疗和商业管理职位。Granowitz博士在达特茅斯学院获得学士学位，在哥伦比亚大学获得医学博士学位。
Craig B. Granowitz, Ph.D,M.D., Ph.D. has been Lexicon Pharmaceuticals, Inc. senior vice president and chief medical officer since August 2021. Dr. Granowitz previously served as chief medical officer of Amarin Corporation plc since 2016. Prior to joining Amarin, Dr. Granowitz served as senior vice president and head of global medical affairs, global human health of Merck & Co., Inc. and in a variety of medical and commercial management positions for Schering-Plough Corporation. Dr. Granowitz received his B.A. from Dartmouth College and his M.D. and Ph.D. from Columbia University.- Craig B. Granowitz博士自2021年8月起担任Lexicon Pharmaceuticals，Inc.高级副总裁兼首席医疗官。格拉诺维茨博士自2016年起担任Amarin Corporation plc的首席医疗官。在加入Amarin之前，Granowitz博士曾担任默克公司高级副总裁兼全球医疗事务、全球人类健康主管，并在Schering-Plough Corporation担任过多个医疗和商业管理职位。Granowitz博士在达特茅斯学院获得学士学位，在哥伦比亚大学获得医学博士学位。
- Craig B. Granowitz, Ph.D,M.D., Ph.D. has been Lexicon Pharmaceuticals, Inc. senior vice president and chief medical officer since August 2021. Dr. Granowitz previously served as chief medical officer of Amarin Corporation plc since 2016. Prior to joining Amarin, Dr. Granowitz served as senior vice president and head of global medical affairs, global human health of Merck & Co., Inc. and in a variety of medical and commercial management positions for Schering-Plough Corporation. Dr. Granowitz received his B.A. from Dartmouth College and his M.D. and Ph.D. from Columbia University.
- Wendy E. McDermott
Wendy E. McDermott自2022年1月起担任Lexicon Pharmaceuticals，Inc.人力资源副总裁。McDermott女士自2019年起担任Rafael Pharmaceuticals，Inc.首席人事官，2017年至2019年担任赛诺菲人力资源副总裁，并在赛诺菲、Schering-Plough Corporation以及烟草、媒体、人才和活动管理行业的其他公司担任各种人力资源职位。麦克德莫特在纽约州立大学普拉茨堡分校获得了学士学位。
Wendy E. McDermott,has been Lexicon Pharmaceuticals, Inc. vice president, human resources since January 2022. Ms. McDermott previously served as chief people officer of Rafael Pharmaceuticals, Inc. since 2019, vice president, human resources of Sanofi from 2017 to 2019 and in a variety of human resources positions with Sanofi, Schering-Plough Corporation and other companies in the tobacco, media and talent and event management industries. Ms. McDermott received her B.A. from State University of New York at Plattsburgh.- Wendy E. McDermott自2022年1月起担任Lexicon Pharmaceuticals，Inc.人力资源副总裁。McDermott女士自2019年起担任Rafael Pharmaceuticals，Inc.首席人事官，2017年至2019年担任赛诺菲人力资源副总裁，并在赛诺菲、Schering-Plough Corporation以及烟草、媒体、人才和活动管理行业的其他公司担任各种人力资源职位。麦克德莫特在纽约州立大学普拉茨堡分校获得了学士学位。
- Wendy E. McDermott,has been Lexicon Pharmaceuticals, Inc. vice president, human resources since January 2022. Ms. McDermott previously served as chief people officer of Rafael Pharmaceuticals, Inc. since 2019, vice president, human resources of Sanofi from 2017 to 2019 and in a variety of human resources positions with Sanofi, Schering-Plough Corporation and other companies in the tobacco, media and talent and event management industries. Ms. McDermott received her B.A. from State University of New York at Plattsburgh.
- Jeffrey L. Wade
Jeffrey L. Wade，自2021年10月起一直担任Lexicon Pharmaceuticals，Inc.总裁兼首席财务官，自1999年加入Lexion Pharmacueticals公司以来，曾担任过一系列财务、企业发展、行政和法律领导职位。在加入Lexicon之前，Wade先生是Andrews&Kurth L.L.P.律师事务所的合伙人，他代表生物技术、信息技术和能源行业的公司进行风险投资融资、公开发行和私募、并购、合作和许可以及其他公司事务。Wade先生是德克萨斯州医疗保健和生物科学研究所和BioHouston的董事会成员。他在德克萨斯大学获得了文学学士和法学博士学位。
Jeffrey L. Wade,has been Lexicon Pharmaceuticals, Inc. president and chief financial officer since October 2021, having previously served in a series of finance, corporate development, administrative and legal leadership positions since joining Lexicon Pharmaceuticals, Inc. in 1999. Before joining Lexicon, Mr. Wade was a partner with the law firm of Andrews & Kurth L.L.P., where he represented companies in the biotechnology, information technology and energy industries in venture capital financings, public offerings and private placements, mergers and acquisitions, collaborations and licensing, and other corporate matters. Mr. Wade is a member of the boards of directors of the Texas Healthcare and Bioscience Institute and BioHouston. He received his B.A. and J.D. from the University of Texas.- Jeffrey L. Wade，自2021年10月起一直担任Lexicon Pharmaceuticals，Inc.总裁兼首席财务官，自1999年加入Lexion Pharmacueticals公司以来，曾担任过一系列财务、企业发展、行政和法律领导职位。在加入Lexicon之前，Wade先生是Andrews&Kurth L.L.P.律师事务所的合伙人，他代表生物技术、信息技术和能源行业的公司进行风险投资融资、公开发行和私募、并购、合作和许可以及其他公司事务。Wade先生是德克萨斯州医疗保健和生物科学研究所和BioHouston的董事会成员。他在德克萨斯大学获得了文学学士和法学博士学位。
- Jeffrey L. Wade,has been Lexicon Pharmaceuticals, Inc. president and chief financial officer since October 2021, having previously served in a series of finance, corporate development, administrative and legal leadership positions since joining Lexicon Pharmaceuticals, Inc. in 1999. Before joining Lexicon, Mr. Wade was a partner with the law firm of Andrews & Kurth L.L.P., where he represented companies in the biotechnology, information technology and energy industries in venture capital financings, public offerings and private placements, mergers and acquisitions, collaborations and licensing, and other corporate matters. Mr. Wade is a member of the boards of directors of the Texas Healthcare and Bioscience Institute and BioHouston. He received his B.A. and J.D. from the University of Texas.
- Alan J. Main
Alan J. Main自2020年9月起担任Lexicon Pharmaceuticals，Inc.创新与化学科学执行副总裁，自2001年加入公司以来曾担任过一系列制造和科学领导职务。Main博士是腔棘鱼公司的总裁兼首席执行官，该公司是利用专有化学技术迅速发现用于药物开发的新化学实体的领导者，直到2001年Lexicon Pharmaceuticals, Inc.收购了腔棘鱼。Main博士之前曾是诺华制药公司美国研究部高级副总裁，在加入腔棘鱼之前曾在该公司工作了20年。Main博士拥有苏格兰阿伯丁大学的学士学位和英国利物浦大学的有机化学博士学位，并在伍德沃德研究所完成了博士后研究。
Alan J. Main,Ph.D . has been Lexicon Pharmaceuticals, Inc. executive vice president of innovation and chemical sciences since September 2020 and previously served in a series of manufacturing and scientific leadership positions since joining Lexicon Pharmaceuticals, Inc. in 2001. Dr. Main was president and chief executive officer of Coelacanth Corporation, a leader in Lexicon Pharmaceuticals, Inc. ing proprietary chemistry technologies to rapidly discover new chemical entities for drug development, until Lexicon Pharmaceuticals, Inc. acquisition of Coelacanth in 2001. Dr. Main was formerly senior vice president, U.S. Research at Novartis Pharmaceuticals Corporation, where he worked for 20 years before joining Coelacanth. Dr. Main holds a B.S. from the University of Aberdeen, Scotland and a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies at the Woodward Research Institute.- Alan J. Main自2020年9月起担任Lexicon Pharmaceuticals，Inc.创新与化学科学执行副总裁，自2001年加入公司以来曾担任过一系列制造和科学领导职务。Main博士是腔棘鱼公司的总裁兼首席执行官，该公司是利用专有化学技术迅速发现用于药物开发的新化学实体的领导者，直到2001年Lexicon Pharmaceuticals, Inc.收购了腔棘鱼。Main博士之前曾是诺华制药公司美国研究部高级副总裁，在加入腔棘鱼之前曾在该公司工作了20年。Main博士拥有苏格兰阿伯丁大学的学士学位和英国利物浦大学的有机化学博士学位，并在伍德沃德研究所完成了博士后研究。
- Alan J. Main,Ph.D . has been Lexicon Pharmaceuticals, Inc. executive vice president of innovation and chemical sciences since September 2020 and previously served in a series of manufacturing and scientific leadership positions since joining Lexicon Pharmaceuticals, Inc. in 2001. Dr. Main was president and chief executive officer of Coelacanth Corporation, a leader in Lexicon Pharmaceuticals, Inc. ing proprietary chemistry technologies to rapidly discover new chemical entities for drug development, until Lexicon Pharmaceuticals, Inc. acquisition of Coelacanth in 2001. Dr. Main was formerly senior vice president, U.S. Research at Novartis Pharmaceuticals Corporation, where he worked for 20 years before joining Coelacanth. Dr. Main holds a B.S. from the University of Aberdeen, Scotland and a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies at the Woodward Research Institute.